DRAP registration delays affecting pharmaceutical exports in Pakistan

ISLAMABAD: Pakistan’s pharmaceutical industry is facing mounting challenges as prolonged registration delays at the Drug Regulatory Authority of Pakistan (DRAP) continue to hinder the approval of new medicines, advanced biologics, and innovative healthcare products.

According to industry stakeholders, hundreds of registration applications remain pending, creating significant uncertainty for pharmaceutical manufacturers and investors. The backlog is not only affecting the introduction of new therapies into the local market but is also threatening Pakistan’s ability to achieve its pharmaceutical export targets.

Industry representatives argue that regulatory bottlenecks are slowing business growth and weakening investor confidence at a time when the country is actively seeking foreign direct investment and export-driven economic expansion.

“Global pharmaceutical markets are advancing rapidly with innovative and life-saving treatments, while local manufacturers continue to face lengthy regulatory procedures,” an industry representative said. “Without timely approvals, Pakistani companies struggle to compete effectively in international markets.”

Experts warn that the delays could have far-reaching consequences for the healthcare sector. Patients may face slower access to modern medicines, while pharmaceutical companies could lose opportunities to expand into regional and international markets.

The situation also poses a challenge to Pakistan’s pharmaceutical export strategy. Industry observers note that international buyers increasingly demand timely product availability and regulatory compliance. Delays in product registration can make it difficult for Pakistani manufacturers to meet market expectations and compete with regional pharmaceutical exporters.

Stakeholders have urged DRAP and relevant government authorities to introduce regulatory reforms, improve processing efficiency, and establish a fast-track mechanism for the approval of critical medicines and export-oriented products.

Industry experts believe that addressing the registration backlog could unlock new investment opportunities, strengthen Pakistan’s pharmaceutical sector, increase export earnings, and improve public access to advanced healthcare solutions.

Keywords: DRAP Registration Delays, Pakistan Pharmaceutical Industry, Drug Registration Pakistan, Pharmaceutical Exports, Healthcare Innovation, DRAP Approval Process, Pharmaceutical Investment Pakistan.